Dyne Therapeutics, Inc. DYN
18.62 USD +0.55 (+3.04%)
At closeNov 10, 2026, 4:05 AM EST
18.30 -0.32 -1.72%
Pre-market · Nov 10, 4:05 AM ET
17.89 Day range 19.00
14.00 52-week range 27.31
- YTD
- -4.81%
- 1 year
- +1.42%
News
benzinga.com Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.92) by 15.22 percent. This is a 39.47 percent decrease over losses of…
globenewswire.com Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
benzinga.com Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Limbach surged 14.7% after beating Q3 estimates and raising FY26 sales guidance; Curis gained 69.5%, while Cenntro plunged 46.5%.
benzinga.com Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15 Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.